Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Clinical trial NCT04312841 · COMPLETED

Trial details

NCT number: NCT04312841
Sponsor: Ohio State University Comprehensive Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

B-Cell Prolymphocytic Leukemia Chronic Lymphocytic Leukemia Peripheral T-Cell Lymphoma Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Sezary Syndrome T-Cell Prolymphocytic Leukemia

Start date: 2020-09-15
Primary completion: 2023-11-24
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.